Project Optimus News Today

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin

Experts say that Project Optimus is a necessary reform in the oncology space, but one that should be applied with caution.

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – Si...

- Data for masked anti-CTLA-4 SAFEbody® ADG126 highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable colorectal cancer with higher, more...

Operator: Greetings and welcome to the BioAtla Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and officials are pushing drugmakers to study lower doses early in the research process.

For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.

Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable. Harsh side effects from powerful cancer drugs have long been accepted as a trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. The U.S. Food and Drug Administration is pushing drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. One group is planning a study to te...